Soliris is a groundbreaking brand that offers revolutionary treatments for various medical conditions. As the first FDA-approved treatment of its kind, Soliris has been extensively studied in over 50 clinical trials and has garnered 15 years of postmarket experience. Soliris treats patients with a range of conditions, including generalized Myasthenia Gravis (gMG) in adults with anti-AChR antibody-positive, Neuromyelitis Optica Spectrum Disorder (NMOSD) in adults with anti-AQP4 antibody-positive, atypical Hemolytic Uremic Syndrome (aHUS) in adults and children, and Paroxysmal Nocturnal Hemoglobinuria (PNH) in adults.

It is important to note that Soliris affects the immune system and may increase the risk of serious infections. Therefore, patients receiving Soliris must be enrolled in the Soliris REMS program, receive meningococcal vaccines, and be closely monitored by their healthcare provider. With a commitment to patient safety and efficacy, Soliris is paving the way for innovative treatments that positively impact the lives of those with complex medical conditions.

Contact your doctor for more information and support